| Literature DB >> 30185903 |
Yuki Ikebuchi1, Shigeki Aoki1, Masashi Honma2, Madoka Hayashi1, Yasutaka Sugamori3, Masud Khan3, Yoshiaki Kariya1, Genki Kato4, Yasuhiko Tabata5, Josef M Penninger6, Nobuyuki Udagawa7, Kazuhiro Aoki3, Hiroshi Suzuki1.
Abstract
Receptor activator of nuclear factor-kappa B (RANK) ligand (RANKL) binds RANK on the surface of osteoclast precursors to trigger osteoclastogenesis. Recent studies have indicated that osteocytic RANKL has an important role in osteoclastogenesis during bone remodelling; however, the role of osteoblastic RANKL remains unclear. Here we show that vesicular RANK, which is secreted from the maturing osteoclasts, binds osteoblastic RANKL and promotes bone formation by triggering RANKL reverse signalling, which activates Runt-related transcription factor 2 (Runx2). The proline-rich motif in the RANKL cytoplasmic tail is required for reverse signalling, and a RANKL(Pro29Ala) point mutation reduces activation of the reverse signalling pathway. The coupling of bone resorption and formation is disrupted in RANKL(Pro29Ala) mutant mice, indicating that osteoblastic RANKL functions as a coupling signal acceptor that recognizes vesicular RANK. RANKL reverse signalling is therefore a potential pharmacological target for avoiding the reduced bone formation associated with inhibition of osteoclastogenesis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30185903 DOI: 10.1038/s41586-018-0482-7
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962